283 related articles for article (PubMed ID: 19358269)
1. Enhancement of immunogenicity of a therapeutic cervical cancer DNA-based vaccine by co-application of sequence-optimized genetic adjuvants.
Ohlschläger P; Quetting M; Alvarez G; Dürst M; Gissmann L; Kaufmann AM
Int J Cancer; 2009 Jul; 125(1):189-98. PubMed ID: 19358269
[TBL] [Abstract][Full Text] [Related]
2. An improved rearranged Human Papillomavirus Type 16 E7 DNA vaccine candidate (HPV-16 E7SH) induces an E7 wildtype-specific T cell response.
Ohlschläger P; Pes M; Osen W; Dürst M; Schneider A; Gissmann L; Kaufmann AM
Vaccine; 2006 Apr; 24(15):2880-93. PubMed ID: 16472545
[TBL] [Abstract][Full Text] [Related]
3. Immunization of mice by the co-administration of codon-optimized HPV16 E7 and lL12 genes against HPV16-associated cervical cancer.
Ajorloo M; Alamdary A; Soleimanjahi H; El Boulani A; Khanizadeh S; Nikoo HR
Microb Pathog; 2019 Jul; 132():20-25. PubMed ID: 31004722
[TBL] [Abstract][Full Text] [Related]
4. Synergistic effect of programmed cell death protein 1 blockade and secondary lymphoid tissue chemokine in the induction of anti-tumor immunity by a therapeutic cancer vaccine.
Moeini S; Saeidi M; Fotouhi F; Mondanizadeh M; Shirian S; Mohebi A; Gorji A; Ghaemi A
Arch Virol; 2017 Feb; 162(2):333-346. PubMed ID: 27699512
[TBL] [Abstract][Full Text] [Related]
5. Suppression of antitumour protective cytotoxic T lymphocyte responses to a human papillomavirus 16 E7 DNA vaccine by coinjection of interleukin-12 complementary DNA: involvement of nitric oxide in immune suppression.
Sin JI
Immunology; 2009 Sep; 128(1 Suppl):e707-17. PubMed ID: 19740332
[TBL] [Abstract][Full Text] [Related]
6. Combination Vaccination With Tetanus Toxoid and Enhanced Tumor-Cell Based Vaccine Against Cervical Cancer in a Mouse Model.
Alson D; Schuyler SC; Yan BX; Samimuthu K; Qiu JT
Front Immunol; 2020; 11():927. PubMed ID: 32547541
[TBL] [Abstract][Full Text] [Related]
7. The combination of TLR-9 adjuvantation and electroporation-mediated delivery enhances in vivo antitumor responses after vaccination with HPV-16 E7 encoding DNA.
Ohlschläger P; Spies E; Alvarez G; Quetting M; Groettrup M
Int J Cancer; 2011 Jan; 128(2):473-81. PubMed ID: 20309939
[TBL] [Abstract][Full Text] [Related]
8. Non-replicating Newcastle Disease Virus as an adjuvant for DNA vaccine enhances antitumor efficacy through the induction of TRAIL and granzyme B expression.
Mohebbi A; Ebrahimzadeh MS; Baghban Rahimi S; Saeidi M; Tabarraei A; Mohebbi SR; Shirian S; Gorji A; Ghaemi A
Virus Res; 2019 Feb; 261():72-80. PubMed ID: 30599161
[TBL] [Abstract][Full Text] [Related]
9. Improving recombinant MVA immune responses: potentiation of the immune responses to HIV-1 with MVA and DNA vectors expressing Env and the cytokines IL-12 and IFN-gamma.
Abaitua F; Rodríguez JR; Garzón A; Rodríguez D; Esteban M
Virus Res; 2006 Mar; 116(1-2):11-20. PubMed ID: 16214252
[TBL] [Abstract][Full Text] [Related]
10. Strong immune responses induced by a DNA vaccine containing HPV16 truncated E7 C-terminal linked to HSP70 gene.
Meshkat Z; Soleimanjahi H; Mirshahabi H; Meshkat M; Kheirandish M; Hassan ZM
Iran J Immunol; 2011 Jun; 8(2):65-75. PubMed ID: 21705833
[TBL] [Abstract][Full Text] [Related]
11. Design and evaluation of a multi-epitope DNA vaccine against HPV16.
Zhu L; Cui X; Yan Z; Tao Y; Shi L; Zhang X; Yao Y; Shi L
Hum Vaccin Immunother; 2024 Dec; 20(1):2352908. PubMed ID: 38780076
[TBL] [Abstract][Full Text] [Related]
12. Eradication of established HPV 16-expressing tumors by a single administration of a vaccine composed of a liposome-encapsulated CTL-T helper fusion peptide in a water-in-oil emulsion.
Daftarian P; Mansour M; Benoit AC; Pohajdak B; Hoskin DW; Brown RG; Kast WM
Vaccine; 2006 Jun; 24(24):5235-44. PubMed ID: 16675074
[TBL] [Abstract][Full Text] [Related]
13. Combined immunization with DNA and transduced tumor cells expressing mouse GM-CSF or IL-2.
Rittich S; Duskova M; Mackova J; Pokorna D; Jinoch P; Smahel M
Oncol Rep; 2005 Feb; 13(2):311-7. PubMed ID: 15643517
[TBL] [Abstract][Full Text] [Related]
14. Low-dose adenovirus vaccine encoding chimeric hepatitis B virus surface antigen-human papillomavirus type 16 E7 proteins induces enhanced E7-specific antibody and cytotoxic T-cell responses.
Báez-Astúa A; Herráez-Hernández E; Garbi N; Pasolli HA; Juárez V; Zur Hausen H; Cid-Arregui A
J Virol; 2005 Oct; 79(20):12807-17. PubMed ID: 16188983
[TBL] [Abstract][Full Text] [Related]
15. Enhancement of therapeutic DNA vaccine potency by melatonin through inhibiting VEGF expression and induction of antitumor immunity mediated by CD8+ T cells.
Baghban Rahimi S; Mohebbi A; Vakilzadeh G; Biglari P; Razeghi Jahromi S; Mohebi SR; Shirian S; Gorji A; Ghaemi A
Arch Virol; 2018 Mar; 163(3):587-597. PubMed ID: 29149434
[TBL] [Abstract][Full Text] [Related]
16. Recombined DNA vaccines encoding calreticulin linked to HPV6bE7 enhance immune response and inhibit angiogenic activity in B16 melanoma mouse model expressing HPV 6bE7 antigen.
Zhao KJ; Cheng H; Zhu KJ; Xu Y; Chen ML; Zhang X; Song T; Ye J; Wang Q; Chen DF
Arch Dermatol Res; 2006 Jul; 298(2):64-72. PubMed ID: 16710741
[TBL] [Abstract][Full Text] [Related]
17. A therapy modality using recombinant IL-12 adenovirus plus E7 protein in a human papillomavirus 16 E6/E7-associated cervical cancer animal model.
Ahn WS; Bae SM; Kim TY; Kim TG; Lee JM; Namkoong SE; Kim CK; Sin JI
Hum Gene Ther; 2003 Oct; 14(15):1389-99. PubMed ID: 14577920
[TBL] [Abstract][Full Text] [Related]
18. Recombinant adeno-associated virus expressing human papillomavirus type 16 E7 peptide DNA fused with heat shock protein DNA as a potential vaccine for cervical cancer.
Liu DW; Tsao YP; Kung JT; Ding YA; Sytwu HK; Xiao X; Chen SL
J Virol; 2000 Mar; 74(6):2888-94. PubMed ID: 10684306
[TBL] [Abstract][Full Text] [Related]
19. A novel "priming-boosting" strategy for immune interventions in cervical cancer.
Liao S; Zhang W; Hu X; Wang W; Deng D; Wang H; Wang C; Zhou J; Wang S; Zhang H; Ma D
Mol Immunol; 2015 Apr; 64(2):295-305. PubMed ID: 25575128
[TBL] [Abstract][Full Text] [Related]
20. A DNA vaccine based on a shuffled E7 oncogene of the human papillomavirus type 16 (HPV 16) induces E7-specific cytotoxic T cells but lacks transforming activity.
Osen W; Peiler T; Ohlschläger P; Caldeira S; Faath S; Michel N; Müller M; Tommasino M; Jochmus I; Gissmann L
Vaccine; 2001 Jul; 19(30):4276-86. PubMed ID: 11457555
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]